HIV controllers: A new evolutionary entity of HIV infection?;Les HIV controllers: Une nouvelle entité évolutive de l'infection par le VIH?

Medecine/Sciences

Volumn 24, Issue 1, 2008, Pages 7-9

  Martinez, Valérie ^a   Autran, Brigitte ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; NONHUMAN; NOTE;

EID: 38849166008     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20082417     Document Type: Note

References (20)

1. Barre-Sinoussi F, Chermann JC, Rey M, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983 ; 220 : 868-71.
2. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996 ; 384 : 529-34.
3. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996 ; 272 : 1167-70.
4. Costagliola D, Downs AM. Incubation time for AIDS. Nature 1987 ; 328 : 582.
5. Buchbinder SP, Katz MN, Hessol NA, et al. Long-term HIV-1 infection without immunologic progression. AIDS 1994 ; 8 : 1123-8.
6. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers : a homogeneous group of HIV-1-infected patients with spontaneous cont rol of viral replication. Clin Infect Dis 2005 ; 41 : 1053-6.
7. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995 ; 332 : 201-8.
8. Candotti D, Costagliola D, Joberty C, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999 ; 58 : 256-263.
9. Magierowska M, Theodorou I, Debre P, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1- infected individuals. Blood 1999 ; 93 : 936-41.
10. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection : a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995 ; 181 : 1365-72.
11. + T cell responses associated with control of viremia. Science 1997 ; 278 : 47-1450.
12. Martinez V, Costagliola D, Bonduelle O, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005 ; 191 : 2053-63.
13. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007 ; 81 : 2508-18.
14. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007 ; 21 : 1043-5.
15. Sajadi MM, Heredia A, Le N, et al. HIV-1 natural viral suppressors : control of viral replication in the absence of therapy. AIDS 2007 ; 21 : 517-9.
16. Saez-Cirion A, Lacabaratz C, Lambotte M, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007 ; 104 : 6776-81.
17. Emu B, Sinclair E, Favre D, et al. Phenatypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005 ; 79 : 14169-78.
18. + T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2007 ; 2 : e321.
19. + elite suppressors despite CTL escape mutations. J Exp Med 2006 ; 203 : 1357-69.
20. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006 ; 80 : 4758-70.